AU5171799A - Method for obtaining (in vitro) recombined polynucleotide sequences, sequence banks and resulting sequences - Google Patents

Method for obtaining (in vitro) recombined polynucleotide sequences, sequence banks and resulting sequences Download PDF

Info

Publication number
AU5171799A
AU5171799A AU51717/99A AU5171799A AU5171799A AU 5171799 A AU5171799 A AU 5171799A AU 51717/99 A AU51717/99 A AU 51717/99A AU 5171799 A AU5171799 A AU 5171799A AU 5171799 A AU5171799 A AU 5171799A
Authority
AU
Australia
Prior art keywords
process according
fragments
polynucleotide sequences
sequences
recombined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU51717/99A
Other versions
AU769516C (en
AU769516B2 (en
Inventor
Daniel Dupret
Fabrice Lefevre
Jean-Michel Masson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteus SA
Original Assignee
Proteus SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteus SA filed Critical Proteus SA
Publication of AU5171799A publication Critical patent/AU5171799A/en
Application granted granted Critical
Publication of AU769516B2 publication Critical patent/AU769516B2/en
Publication of AU769516C publication Critical patent/AU769516C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • C12N15/1027Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method (I) for producing recombined polynucleotide sequences from a library of double-stranded polynucleotide sequences is new and comprises fragmenting and denaturing library sequences, hybridizing them with assembly matrices and selecting sequences with requires properties.. Method (I) for producing recombined polynucleotide sequences from a library of double-stranded polynucleotide sequences is new and comprises: (1) fragmenting the library sequences; (2) denaturing the fragments, optionally in the presence of one or more assembly matrices; (3) hybridizing the fragments with one or more assembly matrices, if these were not present in step (b); (4) ligating the fragments to obtain recombined sequences; and (5) selecting recombined sequences having advantageous properties compared with one or more reference sequences. Independent claims are also included for the following: (1) a recombined polynucleotide sequence obtained and selected by method (I); (2) a vector containing the sequence of (1); (3) a host cell transformed with the sequence of (1) or the vector of (2); (4) a protein encoded by the sequence of (1); (5) a library of polynucleotide sequences as in (1), vectors as in (2), cells as in (3) or proteins as in (4).

Description

PROCESS FOR OBTAINING RECOMBINED NUCLEOTIDE SEQUENCES IN VITRO, LIBRARIES OF SEQUENCES AND SEQUENCES THUS OBTAINED 5 The present invention relates to a method of obtaining recombined nucleotide sequences in vitro. The invention is particularly aimed at generating and then selecting polynucleotide sequences which are liable to have one or several advantageous properties as compared to the corresponding properties of reference sequences and therefore capable of io conferring an improved phenotype and/or of producing improved proteins. By reference sequence is understood a sequence having properties close to those being sought. 15 Different techniques have been developed in order to favor the in vitro recombination between different polynucleotide sequences, among which can be more particularly cited DNA-shuffling (12) and StEP (14), both based on the use of PCR. 20 DNA-Shuffling comprises two steps, the random fragmenting by DNAse I of polynucleotide sequences, and an amplification by PCR in which the fragments previously generated serve as primers. At each step of hybridization, the change of template provokes recombinations at the level of the regions having homologous sequences. A schematic representation of 25 this method is provided in figure 1A . The step consists of mixing different polynucleotide sequences containing various mutations in the presence of a pair of primers. This mixture is subjected to a PCR type of reaction in which the hybridization and 30 polymerization steps are grouped together in a single step of very short duration. These conditions permit hybridization of primers but reduce the duration hence the length of polymerization, in such a way that the fragments which are partially synthesized are randomly hybridized to the polynucleotide sequences having different mutations, thus permitting the recombination. A schematic representation of this method is provided at figure 1B. In each of these two methods, the polymerization step is indispensable 5 to the process of recombination. Thus, according to the polymerase chosen, this polymerization step can bring about undesired supplemental mutations. Moreover, the DNA-shuffling and the step procedures rest on the principle of the hybridization of a "mega-primer" (6) to a template, which likely leads to difficulties in implementation for polynucleotide sequences of size greater than 10 1 5 kbp (11). Finally, these two techniques do not permit the control of the rate of recombination, since they are made randomly in the course of successive polymerization steps. The present invention solves the disadvantages described above by 15 offering a simple method for the preparation of recombined polynucleotide sequences, permitting the generation of polynucleotide sequences capable of displaying advantageous properties as compared to the corresponding properties of the sequences of reference and therefore capable of conferring an improved phenotype and/or producing improved proteins. 20 This goal is attained thanks to a in vitro process for obtaining recombined nucleotide sequences starting from a library of polynucleotide sequences, also designated hereinafter as the initial library, characterized in that it includes the following steps: 25 a) fragmenting a library of double-stranded polynucleotide sequences, b) the denaturation of fragments possibly in the presence of one or several assembling templates, 30 c) the hybridization of said fragments with one or several assembling templates if the template/templates is/are not present in step (b), d) the ligation of said fragments in order to obtain recombined polynucleotide sequences, e) the selection of recombined nucleotide sequences having advantageous properties as compared to the corresponding properties of one or several reference sequences. 5 The process of the invention can include at the output of step (d) and before step (e), the repeating of steps (b), (c) and (d) no longer with the fragments of step (a) but with the products of step (d). This embodiment is particularly useful in the case where, at the outlet io of step (d) all the fragments are not ligated. In this case, the process of the invention moreover includes, at the end of step (d) and before step (e), one or several of the following reaction cycles: - denaturation of the ligated and non-ligated fragments coming out of step (d), possibly in the presence of one or several i5 assembling templates. - hybridization of said fragments with one or several assembling templates if it (they) is(are) not present at the time of the denaturation, - ligation of said fragments. 20 These denaturation, hybridization and ligation reactions are equivalent in steps (b), (c) and (d) but carried out not with the fragments of step (a) but with the ligated and non-ligated fragments coming out of step (d). 25 The process of the invention can moreover include one or several of the following steps: - the separation of the recombined polynucleotide sequences from the assembling template or templates before step (e), - the amplification of the double-stranded recombined 30 polynucleotide sequences before step (e). - the cloning of the recombined polynucleotide sequences possibly after separation of the recombined strands from the template or templates and obtaining of the corresponding double strand before step (e).
4 The ends of the fragments generated at step (a) are such that there can be adjacent hybridization of these ends to the assembling template or templates at step (c) and ligation of these fragments with each other at step (d). The polynucleotide sequences of the library on which the process of the 5 invention is carried out must include zones of homology either between them or with the assembling templates, so as to permit the generating of the ends of the fragments such as described above. One advantageous embodiment of the process of the invention io consists in simultaneously carrying out steps (c) and (d) according to a reaction called RLR for the English expression of "Recombining Ligation Reaction." Besides the advantages previously indicated, the process of the is invention is notable in that it favors and accelerates the random recombination in vitro of polynucleotide sequences and these polynucleotide sequences can be genes. By gene is understood a DNA fragment or sequence associated with a biological function- A gene can be obtained in different manners, such as chemical synthesis, synthesis by polymerization or by extraction of said 20 gene starting with a source of nucleic acids. The in vitro recombination of the polynucleotide sequences of the initial library by the process of the invention therefore permits the obtaining of a new library containing sequences having acquired one or several characteristics of 25 the sequences of the previous library. The process of the invention therefore comprises an in vitro technique of evolution. The process of the invention comprises an alternative to recombinant PCR such as implemented in the techniques of DNA shuffling (12) or of StEP 30 (14), since it does not require the in vitro polymerization step in order to end up with the recombination. To the contrary, the key step of the process of the invention is the step (d) of ligation on an assembling template, which assures a very high degree of faithfulness in the course of the recombination events.
The process of the invention is notable in that it permits a considerable increase in the efficiency of the reassembling of the fragments to ligate. In effect, in the case of a sequence cut up into n fragments, there exists n" possibilities of reassociation of the fragments by using a classical process of 5 ligation (without using a reassembling template which directs the ligation), among which a single form is of interest. In the case of the process of the invention, the ligation is directed by the assembling template, which permits to direct obtention of the single form of interest. 10 The fragmenting of these polynucleotide sequences at step (a) can be done either in a controlled manner or in a random manner. In the case of a fragmenting carried out in a controlled manner, the fragmenting permits controlling with precision the degree of desired is recombination and the position of the points of recombination. According to a preferred embodiment of the process of the invention, step (a) consists of subjecting the polynucleotide sequences of the library to hydrolysis by the action of one or several restriction enzymes- In this way, in one particular embodiment of the process of the invention, the degree of recombination and 20 the position of the points of recombination of the recombined polynucleotide sequences are determined by the fragmenting of step (a). Thus, the larger the number of fragments generated by the sequence, the higher the number of fragments necessary to recompose a sequence, 25 which leads to a higher rate of recombination. Moreover, the nature and the position of the ends of the fragments generated in this embodiment of the process of the invention can be known and controlled, which permits: - controlling with precision the zones where the recombination takes place, or 30 - inducing recombination between polynucleotide sequences, for example genes, if the ends of the fragments are created in zones of homology between these sequences, or in zones of homology between these sequences and the assembling template or templates.
6 In the case of a random fragmenting, any enzymatic or mechanical means known to a person skilled in the art allowing a random cutting of the double-stranded DNA can be used, such as for example DNAse I digestion or 5 sonication. The process of the invention, which permits a considerable increase in the efficiency of reassembling fragments to be ligated, can therefore be applied to the directing of blunt end multi-molecular ligation. In this io application, single or double-stranded oligonucleotides complementary only to the 3' end of a fragment and 5' of the adjacent fragment are used as the assembling template in steps (b) or (c), which permits adjacent hybridization of these two ends on the same template after the denaturation step. Once hybridized, the ends of the fragments can be ligated so as to direct the is direction of the ligation of the blunt ended fragments . The same approach can be contemplated for the positioning of the ligation of fragments having sticky ends. An especially preferred embodiment of the process of the invention 20 consists of adding at step (c) and/or at step (d) enzymes capable of recognizing and of cutting in a specific manner the non-hybridized ends of fragments, when these overlap with other hybridized fragments on the same template. A preferred example of this type of enzyme is the Flap endonuclease enzyme (10). 25 A particular embodiment of the process of the invention therefore consists of using enzymes of the Flap endonuclease type when the fragments generated at step (a) can be overlapping during the hybridization on the assembling template (of) at step (c). 30 In this way, during the hybridization of single stranded DNA fragments on a template, these enzymes have the property of recognizing and of cutting, in a specific manner, the non-hybridized ends of these fragments, when they overlap with other hybridized fragments on the same template. In the course 7 of the hybridization step (c), these enzymes therefore permit increasing the number of adjacent ends that can be ligated at step (d), which is particularly important in the case of fragments obtained by random cutting, as these fragments have zones overlapping with each other when they are hybridized 5 on the assembling template. In a particular embodiment of the process of the invention using a ligase active at high temperature and preferably thermostable at step (d), the endonucleases, capable of recognizing and of cutting in a specific manner the to non-hybridized ends of the fragments such as the Flaps, added at step (c) and/or at step (d) will have the same properties of thermoresistance and of high temperature activity as said ligase. The library of polynucleotide sequences on which the process of the is present invention is carried out can be generated by any method known to a person skilled in the art, for example starting with a wild type gene, by successive steps of directed mutagenesis, by "error prone" PCR (2), by random chemical mutagenesis, by random in vivo mutagenesis, or by combining genes of close or distinct families within the same species or 20 different species so as to obtain a variety of polynucleotide sequences in said library. Among these techniques, the invention more particularly contemplates a process in which the library of double-stranded polynucleotide sequences is 25 obtained by a polymerization chain reaction carried out under conditions that permit creation of random point mutations. The initial library of double-stranded polynucleotide sequences can be composed of synthetic sequences which will be fragmented at step (a) or 30 which can be the fragments of step (a). According to a preferred embodiment for carrying out the process of the invention, step (a) consists of subjecting the polynucleotide sequences of the library to hydrolysis by the action of one or several restriction enzymes.
8 In order to increase the degree of recombination generated by the process of the invention, it is sufficient to increase the number of restriction fragments by using restriction enzymes having a large number of cutting sites 5 on the polynucleotide sequences of the library, or by combining several restriction enzymes- In the case of using a thermostable and thermoactive ligase, the size of the smallest fragment thus generated will advantageously be greater or equal to 40 bp, in order to retain a hybridization temperature compatible with that of the ligation step (d) which is generally of the order of 10 65 0 C. Step (a) can also be carried out by generating a library of fragments by random enzymatic or mechanical treatment. In particular, step (a) can consist of a random treatment with DNAse I of a library of partially heterologous is double-stranded polynucleotide sequences. In the case where a random enzymatic or mechanical fragmenting is used in step (a), this embodiment of the process of the invention has the characteristic of permitting the use of fragments generated by this treatment as templates for each other, for the hybridization in the course of step (c) or of the RLR reaction of the steps (c) 20 and (d) simultaneously. Step (b) can be carried out by combining at least two distinct libraries of fragments separately generated at step (a) starting from the same initial library by different treatments, as for example with different restriction 25 enzymes. In the case of the embodiment of such libraries, the fragments obtained at step (a) are used as templates for each other, for the hybridization during the course of step (c) or the RLR reaction of steps (c) and (d) simultaneously. 30 The fragments of step (a) of the process of the invention can be equally generated by amplification reactions such as PCR realized on the polynucleotide sequences of the library. Two solutions are contemplated- In a first case, the oligonucleotide primers can be conceived in a manner so as 9 to generate fragments having ends which are adjacent all along the length of the assembling sequence. In a second case, the oligonucleotide primers are conceived in a fashion so as to generate fragments having common sequences, these fragments being capable of serving as an assembling 5 template for each other at step (b) or at step (c). The process of the invention permits the combining in a random manner of different fragments obtained at step (a) and of reassembling them during steps (b), (c) and (d) within a polynucloetide sequence- This process therefore reproduces in vitro the recombination phenomena which can occur in vivo by favoring them. The 10 process of the invention is therefore particularly of interest above all for recombining polynucleotide sequences among themselves in order to generate new polynucleotide sequences having interesting properties as compared to the corresponding properties of the reference sequences. is The effectiveness of the recombination' of the process of the invention depends on the number of fragments generated by a polynucleotide sequence at step (a). Consequently, the process of the invention will use polynucleotide sequences having been fragmented into n fragments, n advantageously being greater or equal to three. 20 The assembling template of step (b) or (c) is for example a polynucleotide sequence coming from the initial library or a consensus sequence of said library, single or double-stranded. In the case where the assembling template is incorporated directly at step (c) of the invention, this 25 template must be single-stranded. According to a variant of the process of the invention, the assembling templates of steps (b) or (c) are composed of single or double-stranded oligonucleotides. 30 According to a particular embodiment of the process of the invention, oligonucleotides, single or double-stranded, of variable length, are added at step (b) or (c) in addition to the template. These oligonucleotides are 10 designed (to be capable of being) so as to be substituted for a portion of the fragments of step (c), in effect, their sequence is such that: .. if they are perfectly homologous with the sequence of the 5 fragment which they are replacing, they favor certain combinations, or - if they are partially heterologous with the sequence of the fragment that they are replacing, they introduce one or a more directed supplemental mutations. 10 Before step (e) of the process of the invention, it is possible to separate the recombined polynucleotide sequences from the assembling template thanks to a labeling present in the assembling template or in the recombined polynucleotide sequences- It is in effect possible to label each strand of the is template according to techniques known to a person skilled in the art- For example, the label of the assembling template can be a hapten and the recombined polynucleotide sequences templateare separated from the assembling template by techniques known to a person skilled in the art, such as for example an anti-hapten antibody boundon a support or a biotin 20 streptavidine reaction if the hapten is a biotin label. Other techniques can be employed in order to separate the recombined polynucleotide sequences from the assembling template. The assembling template can also be prepared specifically in a way so as to 25 facilitate its elimination at the end of the process of the invention. It can thus be synthesized by PCR amplification using methylated dATP, which permits its degradation by the restriction endonuclease Dpn 1. In this case, the recombined polynucleotide sequences must not contain methylated dATP. The template can also have been prepared by PCR amplification by using 30 dUTP, which permits its degradation by treatment with a uracyl-DNA glycosylase. Conversely, it is possible to protect the recombined polynucleotide sequences by amplifying them by selective PCR with oligonucleotides having 5' phosphorothioate groups. A treatment with an exonuclease then permits the specific digestionof the assembling template.
* 11 The process of the invention can include before the possible cloning of step (e), a step of amplification of the recombined polynucleotide sequences. Any amplification technique is acceptable, notably a PCR amplification. One 5 of the most simple consists of carrying out a PCR which permits specific amplification of the recombined polynucleotide sequences owing to primers which can only be hybridized at the ends of the recombined sequences. The PCR products are then cloned in order to be characterized and the polynucleotide sequences having advantageous properties as compared to 1o the corresponding properties of the reference sequences are selected. The invention has for its object the generation of polynucleotide sequences liable to have advantageous properties as compared to the corresponding properties of reference sequences. The recombined 15 polynucleotide sequences obtained at step (d) and possibly cloned are screened by any appropriate means in order to select the recombined polynucleotide sequences or the clones having advantageous properties as compared to the corresponding properties of the reference sequences By advantageous property is understood to be, for example, the thermostability of 20 an enzyme or its abilityto function under conditions of pH or of temperature or of saline concentration more adapted to an enzymatic process than the control proteins usually used for said process- Forexample. such a process can be an industrial process to breakdown textile fibers or bleaching paper pulps or producing flavors in the dairy industry, the processes of biocatalysis 25 for the synthesis by an enzymatic pathway of new therapeutic molecules, etc. According to an advantageous embodiment of the process of the invention, the polynucleotide sequence library can therefore be the result of a screening having permitted selection by any appropriate means of 30 polynucleotide sequences having advantageous properties as compared to control sequences- The sequences selected in this way comprise a limited library.
12 But, it is also possible to start from a non-limited library in order to preserve the representation of the properties contained in that library. The sequences coding for the protein or proteins having one or more 5 advantageous properties as compared to the reference proteins are thus selected, by in vivo or in vitro screenings, and can be used to form a new library for a possible repeating of the process of the invention. One advantageous embodiment of the process of the invention therefore consists of using as the library several polynucleotide sequences selected after a first i0 implementation of the process of the invention, possibly mixed with other polynucleotide sequences. Among the screening techniques which can be applied to each of the clones of step (e). the screening techniques in vitro give rise to the advantage of being free of problems of cellular physiology, and of any drawbacks tied to the in vivo expression cloning. Moreover, this type of 15 screening is easily automated, which permits screening a higher number of recombined polynucleotide sequences. The invention also relates to a recombined polynucleotide sequence obtained by a process according to the invention, as well as to a vector 20 containing such a recombined polynucleotide sequence, a cellular host transformed by a recombined polynucleotide sequence or by a vector of the invention, as well as a protein coded by this recombined polynucleotide sequence. The invention includes as well the corresponding libraries of recombined polynucleotide sequences, vectors, cellular hosts, or proteins. 25 Other advantages and features of the invention will appear from the examples of carrying out the invention, which follow and which are referred to in the attached drawings in which: 30 Figure 1 is a schematic representation of the processes of the prior art corresponding respectively to DNA-shuffling (figure 1A) and to StEP (figure 1B).
13 Figure 2 is a schematic representation of an example of carrying out the process of the invention and of certain of its variations and applications. Figure 3 represents the positions of the ten zones of mutations (Pvu i 5 and Pst /) carried by each mutant of the ponB gene used for the examples of the implementation of the invention. Figure 4 represents the position of the primers used as compared to the sequence of the ponB gene. 10 Figure 5 represents the migration on agarose gel of RLR and of PCR reaction products of these RLR reactions. Figure 6 represents the position of the mutations as compared to the 15 restriction fragments. I- EXAMPLE The process of the invention was put into practice starting from a library of gene mutants of ponB, coding for the PBP1b of E. coli (1). Ten 20 mutants of this gene were used. The gene sequence of each mutant differs from that of the native gene by a non homologous zone of thirteen to sixteen bases in length resulting from the substitution of five initial codons by five alanine codons according to the technique described by Lefevre et at (8). 25 The substitution carried by each mutant is characterized by the presence of a unique site of the restriction enzyme Pvu // surrounded by two Pst / enzyme sites, which permits the mutants to be distinguished from each other by their digestion profile with these restriction endonucleases. Figure 3 represents the positions of the ten zones of mutations (Pvu // and Pst /) 30 carried by each mutant. After PCR amplification of the genes of the ten mutants, the PCR products were purified, mixed in equimolar quantity in order to form the library. The polynucleotide sequences of this library were digested with the restriction 14 enzymes Hinf I and Bsa 1, in such a way as to generate libraries of restriction fragments. The restriction fragments were then incubated with various amounts of the wild type template, at different quantities, in the presence of a thermostable ligase. After several denaturation/hybridization/ligation cycles, a s fraction of the reaction mixture was used to carry out a PCR amplification with a couple of primers specific to the 5' and 3' ends of the genes of the mutants and non-specific to the 5' and 3' ends of the wild type template. The amplification product was cloned and the obtained clones were analyzed for their digestion profile with the Pvu I/ or Pst I restriction endonucleases. The 1o obtained profiles permitted the determination of which fragment(s) of the mutants had been able to be recombined with the others in order to form an entire gene. II MATERIALS is 1) Strains and plasmids The strain MC1061 (F araD139, a (ara-Ieu)7696, gaIE15, gaiK16, A (lac)X74, rpsL (StrR), mcrA mcrB1, hsdR2 (rk mif)) is derived from Escherichia coli K12. 20 The vector pARAPONB stems from the vector pARA13 (3) in which the ponB gene carrying a thrombin-cutting site (9) was introduced between the restriction sites Aco I and Nar /. The vector pET26b+ is one of the pET vectors developed by Studier and Moffatt (13) and commercialized by 25 NOVAGEN Corporation. 2) Oliqonucleotides The oligonucleotides were synthesized by ISOPRIM corporation (Toulouse)- The oligonucleotide sequences are reported in Table I below. 30 Table I ligo N 5' ACTGACTACCATGGCCGGGAATGACCGCGAGCC3' Oligo E ' 5' CCGCGGTGGAGCGAATTCTAAUACTACCAAACATATCC 3 Oirgo Ml 5' GCGCCTGAATATTGCGGAGAAAAGC 3 Oligo M2 5' ACAACCAGATGAAAAG
GGGTATATC
3 ' Oligo Al 5'ACTGACTACCATGGCC 3 Oligo A2 5' CCGCGGTGGAGCGAATTC 3' 3) Reagents The restriction and modification enzymes cited in Table i below were used according to the recommendations of the suppliers. Table Il 10 Enzyme Concentration Supplier Ncol 10 U/pl New England Biolabs PstI 20 U/pl New England Biolabs Eco RI 20 u/pl New England Biolabs Bsa / 5 U/ld New England Biolabs Hinf 1 10 U/I New England Biolabs Pvu 1/ 10 U/pl New England Biolabs T4 DNA ligase 400 U/pfl New England Biolabs Taq DNA polymerase 5 UI 1 Ll PROMEGA AMPLIGASE 100 U/91 EPICENTRE The buffers used are reported in Table IlIl below Buffers Composition T Tris HCI 10 mM, pH 8.0 Polymerization 20X Tris HCI 100 mM pH 8.3, MgCl 2 15 mM, KCI 500 mM, 1.0% TRITON X100@ 16 Restriction A 1OX 500 mM NaCl, 100 mM Tris HCI pH 7.9, 100mM MgCl 2 , 10mM DTT Restriction B 10X 1 M NaCI, 500 mM Tris HCI pH 7.9, 100 mM MgCl 2 , 10 mM DTT Restriction C 1oX 500 mM NaCI, 1 M Tris HCI pH 7.5, 100 mM mM MgC 2 , 0.25% TRITON X100@ AMPLIGASE 1oX 200 mM Tris HCI pH 8.3, 250 mM KCI, 100 mM MgCI 2 , 5 mM NAD, 0.1% TRITON X100@ Ligation 10X 500 mM Tris HCI pH 7.5, 100 mM MgC1 2 , 100 mM DTT, 10 mM ATP, 250 g/ml BSA Ill PREPARATION OF THE TEMPLATE The wild type ponB gene was amplified by a PCR reaction step by 5 using as primers the oligonucleotides M1 and M2 (Fig- 4). Five PCR reactions were prepared by adding 50 ng of pPONBPBR plasmid carrying the wild type gene (7) to a mixture containing 10 pl of polymerization buffer, 10 pI of dNTPs 2mM, 20 pmol of each oligonucleotide M1 and M2, and 5U of Taq DNA polymerase, in a final volume of 100 pI. These mixtures were incubated to in Perkin-Elmer 9600 Thermocycler according to the following program: (94 *C - 2 min.) - (94 0 C 15 sec. - 60*C 30 sec. -72 0 C 1 min.) x 29 cycles - (72 0 C -3 min.). The product of the five PCR was mixed and loadedon a 1% is TBEagarose gelAfter migration and staining of the gel with ethidium bromide, the band at 2651 bp, corresponding to the ponB gene amplification product surrounded by two fragments of 26 bp and 90 bp respectively, was visualized by trans-illumination under ultraviolet, and cut out with a scalpel in order to be purified with the QUIAquick system (QIAGEN). Allthe DNA thus purified was 20 eluted in 120 lLI of buffer T. The concentration of this DNA was approximatively 100 ng/i as measured by its absorbanceat 260 nm . IV PREPARATION OF THE LIBRARY 1) Amplification of the mutant genes The genes of the ten mutants were separately amplified by a PCR 5 reaction witholigonucleotides N and E. These oligonucleotides introduce respectively the restriction sites Nco I and Eco RI, permitting the cloning of the products obtained with these two sites. Each PCR reaction was prepared by adding 50 ng of the plasmid 10 carrying the mutant gene to a mixture containing 10 d of polymerization buffer, 10 fd of dNTPs 2mM, 20 pmol of each oligonucleotide N and E, and 5U of Taq DNA polymerase, in a final volume of 100 pJ. This mixture was incubated in a Perkin-Elmer 9600 thermocycler according to the following program: (94*C - 2 min.) - (94*C 15 sec. - 60*C 30 sec. - 72*C 1 min.) x 29 15 cycles - (72 0 C - 3 min.). The specificity of the genetic amplification was verified by restriction profile with the Pvu 11 endonuclease, by incubating 5 RI of each PCR product 1 hour at 37 *C in a mixture containing 3 14 of restriction buffer A and 5U of the 20 Pvu // enzyme in a final volume of 30 ptl. 15 pi of that digestion reaction were loaded on a TBE 1% agarose gel. After migration and staining with ethidium bromide, the gel was exposed to ultraviolet. The visualization of the restriction fragments permitted confirmation of the specificity of the genetic amplification of each mutant gene. 25 In parallel, 3 41 of each PCR reaction were loaded on a TBE 1% agarose gel . After migration, the gel was treated as above. The intensity of each band permitted the assessment that the genetic amplifications had the same yield. 30 2) Creation of libraries of restriction fragments.
10 50 p. of each of the ten PCR were mixed and loaded on a 1% TBE agarose gel. After migration and staining with ethidium bromide, the band at 2572 bp, corresponding to the amplification product of the genes of the ten mutants, was cut out with a scalpel and purified with the Quiaquick system (QIAGEN) s Allthe DNA thus purified was eluted in 120 p1 of buffer T. The concentration of this DNA was approximately 100 ng/ptl according to its absorbance at 260 nm. In order to generate the libraries of restriction fragments, 100 41 of this DNA were incubated for one hour at 50*C in a mixture containing 12 pL of 1o restriction buffer B, 1.2 p of BSA (at 10 mg/ml), 25 U of the enzyme Bsa / and 4 p of water. Then, 2 pl of restriction buffer B, 2 td of BSA (at 1 mg/ml). 50 U of the enzyme Hint / and 11.5 j4I of water were added to the mixture, which was incubated for one hour at 37 *C. The digestion mixture was purified on a QlAquick column (QIAGEN), and eluted with 30 pl of buffer T. 1 p11 of this is eluate was loaded on a 1% TBE agarose gel in order to verify that the digestion had been total, and that it had generated 6 restriction fragments, and consequently six libraries of fragments, of 590 bp, 500 bp, 472 bp, 438 bp, 298 bp and 274 bp. The concentration of this DNA was approximately 250 ng/pl according to its absorbance at 260 nm. 20 V RLR (Recombinating Ligation Reaction). The RLR reaction (Recombining Ligation Reaction) was carried out by incubating determined quantities of restriction fragments Hinf I - Bsa I from the genes of ten mutants with the complete template (i.e., the wild type ponB 25 gene), in the presence of a thermostable DNA ligase. The table IV below reports the composition of the mixtures for RLR. 30 Table IV 19 RLR 1 RLR 2 RLR 3 RLR 4 T Fragments Hinfl-Bsa/ 0.
5 p l 141 2 pl 5 I 5 p1 of ten mutants (100 ng/gl) Wild type ponB 0.6 pl 1.
2 pl 2.44i 6 pl 6G-1 template (100 ngipl) AMPLIGASE 1OX Buffer 2 11 2 p 2 pl 2 p. 2 g1 AMPLIGASE (25 U/pl) 1 p1 1 p1 1 p. 1 p.
1
H
2 0 qsp 20 qsp 20 qsp 20 qsp 20 qsp 20 si P 1 .1 p.1 The negative control is identical to the reaction of RLR4, but does not contain thermostable DNA ligase. These different mixtures were covered with s a drop of mineral oil and incubated in a Perkin-Elmer 9600 thermocycler in 200 p 1 microtubes according to the following program: ( 94 *C, 5 min.) (94 0 C, 1 min. - 65 0 C, 4 min.) x 35 cycles. 10 p1 of each RLR reaction were then added to a PCR reaction mixture 10 containing 10 pl of polymerization buffer, 10 41 of 2 mM dNTPs, 40 pmol of each oligonucleotide Al and A2, and 5 U 6f Taq DNA polymerase in a final volume of 100 p 1 1. This mixture was incubated in a Perkin-Elmer 9600 thermocycler according to the following program: (94*C, 5 min.) - (94-C, 30 sec. - 46*C, 30 sec. - 72 0 C, 1 min.) x 29 cycles - (72*C, 2 min.). This PCR 15 reaction permitted specific amplification of the ligation products formed in the course of the RLR reaction, without amplifying the template, since the oligonucleotides Al and A2 are not able to hybridize with the template (it). as shown in Figure 4. 20 5 1 of each RLR reaction and 10 p. of each of the previous PCR reactions were loaded on a 1% TBE agarose gel After staining with ethidium bromide, the gel was exposed to ultraviolet light, as shown in Figure 5.
The analysis of this gel reveals that only the reaction of RLR4 contains, as the negative control, restriction fragments still visible (tracks 4 and 5). 5 The absence of PCR product for the negative control (track 10) reveals not only that the PCR reaction is specific (no amplification of the complete template), but also that the restriction fragments present in the mixture cannot be substituted for the primers to generate a contaminant PCR product under the chosen conditions. In parallel, the presence of a unique band at about 10 2500 bp in tracks 6, 7 and 8 demonstrates that an RLR product was able to be amplified by PCR for the RLR1, 2 and 3 reactions. These three RLR reactions therefore permitted the regeneration of one or more of the complete genes starting from six libraries of restriction fragments. 15 VI ANALYSIS OF THE AMPLIFICATION PRODUCTS OF THE RLR REACTIONS 1) Cloning The PCR amplification products of the RLR 1, 2 and 3 reactions were 20 purified with the Wizard PCR Preps system (PROMEGA) and eluted in 45 jfl of buffer T. 6 41 of each purified PCR were incubated 1 hour at 37 *C in a mixture containing 3 pl of restriction buffer C, 3 ±l of BSA (1 mg/ml), 20 U of the Eco RI enzyme, 10 U of the Nco I enzyme and 15 gl of water. 25 In parallel, two vectors (pARAPONB and pET26b3+) were prepared for the cloning. These vectors were linearized by incubating 3 pig of these plasmids for 2 hours at 37 0 C, in a mixture containing 3 Iil of restriction buffer C, 3 pl of BSA (1 mg/ml), 20 U of the Eco RI enzyme, 10 U of the Nco I enzyme and 19 pil of water. 30 The linearized vectors as well as the digested PCR were purified on a TBE 1% agarose gel with the QlAquick system (QUIAGEN). Each vector or each digested PCR was eluted in 30 pl of buffer T.
The ligation of each PCR digested with each of the vectors was carried out according to the conditions described in table V below, and incubated at 16 *C for 16 hours. 5 Table V Ligation with the vector Ligation with the vector pET26b+ pARAPONB LpAR1 LpAR2 LpAR3 TLpAR LpET1 LpET2 LpET3 TLpET PCR amplification 4 sI - - - 4 Fl - RLR 1 digested Nco - Eco RI PCR amplification - 4 id - - - 4 pt - RLR 2 digested Nco I - Eco RI PCR amplification - - 4 F - -- 4 941 RLR 3 digested NCO I - EcoRi Vector pARAPONB 1 pl 1 pd 1 F1 1 I digested Nco I Eco R1 vector pET26b+ - - - - 1 1 1 1 1 . 1 p1 digested Nco I Eco RI Liga-on Biffer 29pl 2gp 2 pi 2 p 2 pL 2 I 2 pi 2 pd Ligase 1 1 FI 191 id 11 i Hi2O 12 pl 12 124 1 16,d 1291 12 41 12 9 16141 200 pl of chimiocompetent MC1061 cells (4) were transformed with 10 pl of each ligation by a thermal shock (5), and the cells thus transformed were to spread over a selection medium No clone was obtained after transformation of ligation controls TLpAR and TLpET, thus indicating that the Nco I - Eco R1 vectors pARAPONB and pET26b+ cannot undergo an intramolecular ligation. 15 2) Screening by PCR A first screening of the clones obtained after transformation of the ligations with the vector pARAPONB was carried out by PCR. 42 colonies, 14 5 from each ligation LpAR1, LpAR2 and LpAR3, were resuspended individually in a PCR mixture containing 5 [d of polymerization buffer, 40 pmol of each oligonucleotide Al and A2, 5 jd of 2 mM dNTPs and 5U of Taq DNA polymerase in a final volume of 50 jLl. A negative control was obtained by adding to the PCR mixture 50 rig of the plasmid pBR322 in place of the 1o colony. These 43 tubes were incubated in a Perkin-Elmer 9600 thermocycler according to the following program: (94*C, 5 min.) - (94*C, 30 sec. - 46*C, 30 sec. - 72 0 C, 1 min.) x 29 cycles - (72*C, 2 min.). 5 1d of each of these PCR reactions were then incubated for 1 hour at 37 "C in a mixture containing 2 pl of restriction buffer A, 2 1 .d of BSA (1 mg/ml) and 5 U of the restriction enzyme is Pvu // in a final volume of 20 ld. 10 pl of each of these digestions were loaded on a TBE 1% agarose gel in parallel with 5 pLl of each non-digested PCR (thus avoiding possible confusion of non-specific bands of the PCR with a fragment obtained by 20 restriction digestion). After migration and staining of this gel with ethidium bromide, the bands resulting from the digestion by the enzyme Pvu 1/ were analyzed in order to determine which fragment(s) of initial mutants was/were associated with the others in order to reconstruct an entire gene. This screening reveals the presence of 27 genes carrying one mutation, 7 genes 25 carrying two mutations and 8 genes no longer carrying any mutation. 3) Screening by plasmidic DNA minipreparation The second screening was effected by carrying out an extraction of the 30 plasmidic DNA (5) from 21 clones resulting from the transformation of the ligations with the vector pET26b+ (7 clones of each ligation). 5 141 of the plasmidic DNA thus obtained for each clone were incubated for 1 hour at 37 0 C in a mixture containing 1 pl of restriction buffer C, 6 U of the enzyme Pst /, 3 U of the enzyme Nco / and 6 U of the enzyme Eco RI in a final volume of 10 p1. 5 p1 of each of these digestions were loaded on a TBE 1% agarose gel. After migration and staining of this gel with ethidium bromide, the bands resulting from the digestion by the Pst I enzyme were analyzed in order to 5 determine which fragment(s) of the initial mutants had associated with the others in order to reconstruct an entire gene. This screening reveals the presence of 13 genes carrying a mutation, 5 genes carrying two mutations and 3 genes no longer carrying a mutation. 10 4) Statistical Analysis of the recombinations. According to the position of each mutation as compared to the cutting sites of the enzymes Hinf / and Bsa 1, as represented in Figure 6, it is possible to calculate the probability of obtaining in the course of the RLR reaction the creation of a gene carrying 0, 1, 2, 3, or 4 of the mutations of the initial genes. 15 Thus, by considering that the RLR reaction is totally random the probabilities P are as follows: P(0 mutation) = 30.24% 20 P(l mutation) = [404% ~ 4- 1j0_-a 1j0-(a + n) P(2 mutations) = L ( [Jill ( )21.44% a-1 a+n 25 P(3 mutations)= 0 U-Ln = 4.04% P(4 mutaTions) = = 0.24% The two screenings carried out give results close to these statistical 30 predictions, as reported in table VI below, thus indicating that the RLR reaction is quasi-random. A slightly higher proportion of genes carrying one mutation, to the detriment of the genes carrying zero mutation, is observed.
This phenomenon could be attributed to a weak toxicity of the ponB gene already observed and to the slight of expression leakage of vectors pARAPONB and pET26b*, which would favor the selection of genes carrying an inactivating mutation. 5 Table :VI % 0 mutation 1 mutation 2 mutations 3 mutations 4 mutations Statistics 30.24 44.04 21.44 4.04 0.24 PCR 21 63 16 0 0 Screening Mini- 14 62 24 0 0 preparation Screening 10 BIOGRAPHICAL REFERENCES 1) Broome-Smith J.K, Edelman Al, Yousif S. and Spratt B.G., (1985), The nucleotide sequence of the ponA and ponB genes 5 encoding penicillin-binding proteins 1A and 1B of Escherichia coli K12, Eur. J. Biochem., 147, 437-446. 2) Caldwell R.C. and Joyce G., 1992, Randomization of genes by PCR mutagenesis, PCR Methods and Application, 2, 28-33. 10 3) Cagnon C., Valverde V. and Masson J.-M., (1991), A new family of sugar inducible expression vectors for Escherichia coli, Prot. Eng., 4, 843-847. 15 4) Hanahan D., (1985), Techniques for transformation of Escherichia coli, in DNA cloning: a practical approach, Glover D.M. (ed), IRL Press, Oxford vol 1, 109-135. 5) Maniatis T., Fristch E.F. and Sambrook J., (1982), Molecular 20 cloning. A laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 6) Landt et al., Gene, 96, 125-128, 1990. 25 7) Lefbvre F., Topological Analysis of the Penicillin Binding Protein 1 b of Escherichia coli, 1997, These. 8) Lefevre F, Remy M H. and Masson J.M., 1997 (a), Alanine stretch scanning mutagenesis: a simple and efficient method to 30 probe protein structure and function, Nuc. Acids Res., 25, 447 448. 9) Lef&vre F., Remy M H. and Masson J.M., 1997 (b), Topographical and functional investigation of Escherichia coli Penicillin-Binding Protein 1b by alanine stretch scanning mutagenesis, J. Bacterial., 179, 4761-4767. 10) Lyamichev V., Mast A.1., Prudent J.R., Kaiser M.W, Takova T, 5 Kwiatkowski R.W., Sander T.J., de Arruda M., Arco D.A., Neri B.P. and Brown M.A.D., 1999, Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes, Nature Biotechnology, 17, 292-296. 10 11) Picard et al., Nuc. Acids Res., 22, 2587-2591, 1994. 12) Stemmer W.P.C-, (1994), Rapid evolution of a protein in vitro by DNA shuffling, Nature, 370, 141-144. 15 13) Studier F.W. and Moffatt B.A., 1986, Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes, J. Mol. Biol, 189, 113-130. 14) Zhao, H., Giver L, Shao Z., Affholter J.A. and Arnold F., 1998, 20 Molecular evolution by staggered extension process (StEP) in vitro recombination, Nature Biotech., 16, 258-261.

Claims (37)

1. Process of obtaining in vitro recombined polynucleotide sequences starting from a library of polynucleotide sequences characterized in 5 that it includes the following steps: a) the fragmenting of a library of double-stranded polynucleotide sequences, b) the denaturation of the fragments possibly in the presence of one or several assembling templates, 10 c) the hybridization of said fragments with one or several assembling templates if it/they is/are not present in step (b), d) the ligation of said fragments in order to obtain recombined polynucleotide sequences, e) the selection of the recombined polynucleotide sequences is having advantageous properties as compared to the corresponding properties of one or several reference sequences.
2. Process according to claim 1, characterized in that it includes at the 20 end of step (d) and before step (e), the repeating of steps (b), (c) and (d) with the ligated and non-ligated fragments resulting from step (d).
3. Process according to one of claims 1 or 2, characterized in that it 25 includes the separation of the recombined polynucleotide sequences from the assembling template or templates before step (e)
4. Process according to any one of the previous claims, characterized 30 in that it includes the amplification of the double-stranded recombined polynucleotide sequences before step (e).
5. Process according to any one of the previous claims, characterized in that it includes before step (e), the cloning of recombined 28 polynucleotide sequences possibly after separation of the recombined strands of the template or templates and obtaining the corresponding double strand. 5
6. Process according to any one of the precious claims, characterized in that the ends of the fragments generated at step (a) are such that there can be adjacent hybridization of these ends on the assembling template or templates at step (c) and ligation of these fragments with each other at step (d). 10
7. Process according to any one of the previous claims, characterized in that the polynucleotide sequences of the initial library have zones of homology either between themselves or with the assembling templates, so as to generate at step (a) ends of fragments which 15 permit the adjacent hybridization of these ends on the assembling template or templates at step (c) and ligation of these fragments with each other at step (d).
8. Process according to any one of the previous claims, characterized 20 in that the steps (c) and (d) are carried out simultaneously.
9. Process according to any one of the previous claims, characterized in that the fragmenting of the polynucleotide sequences at step (a) is carried out in a controlled or a random manner. 25
10. Process according to any one of the previous claims, characterized in that step (a) consists of subjecting the polynucleotide sequences of the initial library to a hydrolysis by the action of one or several restriction enzymes. 30
11. Process according to any one of the previous claims, characterized in that the degree of recombination and the position of the points of recombination of the recombined polynucleotide 29 sequences are determined by the fragmentation described in step (a) if it is carried out in a controlled manner.
12. Process according to any one of claims 1 to 9, characterized in 5 that the random fragmenting of the polynucleotide sequences at step (a) is carried out by any known enzymatic or mechanical means
13. Process according to any one of the previous claims, 10 characterized in that enzymes capable of recognizing and of cutting the non-hybridized ends of the fragments in a specific manner are added at step (c) and/or step (d), when said ends overlap with other hybridized fragments on the same template. 15
14. Process according to claim 13, characterized in that the enzyme Flap endonuclease is added at step (c) and/or step (d).
15. Process according to any one of the previous claims, characterized in that a ligase active at high temperature and preferably 20 thermostable is used at step (d).
16. Process according to claims 13 and 14, characterized in that the endonucleases capable of recognizing and of cutting in a specific manner the non-hybridized ends of the fragments added at step (c) 25 and/or at step (d) have the same thermoresistance and high temperature activity properties as the ligase used at step (d).
17. Process according to any one of the previous claims characterized in that the initial library of polynucleotide sequences is generated 30 starting from a native gene by steps of successive directed mutagenesis, by error prone PCR, by random chemical mutagenesis, by in vivo random mutagenesis, or by combining genes of close or distinct families within the same or different 3U species in such a way as to arrange a variety of polynucleotide sequences in an initial library.
18- Process according to any one of claims 1 to 16, characterized in 5 that the initial library of double-stranded polynucleotide sequences is formed of synthetic sequences which will be fragmented at step (a) or which can form the fragments of step (a).
19. Process according to any one of claims 1 to 11, 13 to 18, 10 characterized in that the step (a) consists of subjecting the initial library to a hydrolysis by the action of restriction enzymes having a large number of cutting sites on the polynucleotide sequences of the initial library, or by combining several restriction enzymes. 5
20- Process according to any one of claims 1 to 9 and 12 to 18, characterized in that the step (a) consists of a random treatment with the DNAse I of an initial library of partially heterologous, double-stranded polynucleotide sequences. 20
21. Process according to any one of claims 12 or 20, characterized in that fragments generated by a random treatment are used as templates for each other, for the hybridization in the course of step (c) or the RLR reaction of steps (c) and (d) simultaneously, 25
22. Process according to any one of claims 10 or 19, characterized in that step (b) is carried out by combining at least two distinct libraries of fragments generated separately at step (a) starting from the same initial library by a treatment with different restriction enzymes. 30 23 Process according to claim 22, characterized in that the fragments obtained at step (a) by a treatment with restriction enzymes are used as templates for each other, for the hybridization during step (c) or of the RLR reaction of steps (c) and (d) simultaneously. 31
24. Process according to any one of claims 1 to 9, 11, 13 to 17 characterized in that the fragments of step (a) are obtained by amplification reactions directed by the polynucleotide sequence of the initial library, 5
25- Process according to claim 24, characterized in that the amplification reactions are carried out with oligonucleotide primers permitting generation of fragments whose ends are adjacent along the whole length of the assembling sequence. 10
26- Process according to claim 24, characterized in that the amplification reactions are carried out with oligonucleotide primers permitting generation of fragments having common sequences, said fragments serving as an assembling template for each other at step is (b) or at step (c).
27- Process according to any one of the previous claims, characterized in that at step (a) the initial library is fragmented into n fragments, n being greater than or equal to 3. 20
28. Process according to any one of claims 1 to 18, 24 to 27, characterized in that the assembling template at step (b) or (c) is a polynucleotide sequence resulting from the initial library or a single or double-stranded consensus sequence of said library. 2 5
29. Process according to any one of claims 1 to 19, 24 to 27, characterized in that single or double-stranded oligonucleotides complementary just at the 3' end of one fragment and at the 5' end of the adjacent fragment are used as assembling template at steps 30 (b) or (c).
31. Process according to any one of the previous claims, characterized in that single or double-stranded oligonucleotides, of variable length, are added at step (b) or (c) in addition to the template.
32. Process according to any one of the previous claims, characterized in that, before step (e) the recombined polynucleotide sequences are separated from the assembling template thanks to a s label present on the assembling template or on the recombined polynucleotide sequences
33. Process according to any one of the previous claims, characterized in that the recombined polynucleotide sequences to obtained at step (d) and possibly cloned are screened by any appropriate means in order to select the recombined polynucleotide sequences or the clones having advantageous properties as compared to the corresponding properties of the reference sequences. is
34. Process according to any one of the previous claims, characterized in that the initial library of polynucleotide sequences is formed by one or several limited librarys prepared by a process according to any one of claims 1 to 33, possibly mixed with other 20 polynucleotide sequences.
35.A recombined polynucleotide sequence having one or several advantageous properties as compared to the corresponding properties of reference sequences obtained and selected by a 25 process according to anyone of claims 1 to 34.
36. A vector containing a polynucleotide sequence according to claim 35. 30
37. A cellular host transformed by a recombined polynucleotide sequence according to claim 35 or by a vector according to claim 36. 3.,
38.A protein encoded by a recombined polynucleotide sequence according to claim 37.
39. A library formed from recombined polynucleotide sequences 5 according to claim 35, or of the vector according to claim 36, or of host cells according to claim 37, or of proteins according to claim 38.
AU51717/99A 1998-08-12 1999-08-11 Method for obtaining (in vitro) recombined polynucleotide sequences, sequence banks and resulting sequences Ceased AU769516C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9810338 1998-08-12
FR9810338A FR2782323B1 (en) 1998-08-12 1998-08-12 PROCESS FOR THE IN VITRO PRODUCTION OF RECOMBINANT POLYNUCLEOTIDE SEQUENCES, SEQUENCE BANKS AND SEQUENCES THUS OBTAINED
PCT/FR1999/001973 WO2000009679A1 (en) 1998-08-12 1999-08-11 Method for obtaining in vitro recombined polynucleotide sequences, sequence banks and resulting sequences

Publications (3)

Publication Number Publication Date
AU5171799A true AU5171799A (en) 2000-03-06
AU769516B2 AU769516B2 (en) 2004-01-29
AU769516C AU769516C (en) 2004-11-18

Family

ID=9529621

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51717/99A Ceased AU769516C (en) 1998-08-12 1999-08-11 Method for obtaining (in vitro) recombined polynucleotide sequences, sequence banks and resulting sequences

Country Status (12)

Country Link
EP (2) EP1104457B1 (en)
JP (1) JP4448619B2 (en)
AT (1) ATE309342T1 (en)
AU (1) AU769516C (en)
CA (1) CA2339901C (en)
DE (1) DE69928263T2 (en)
DK (1) DK1104457T3 (en)
ES (1) ES2253901T3 (en)
FR (1) FR2782323B1 (en)
IL (2) IL141373A0 (en)
NO (1) NO20015787L (en)
WO (1) WO2000009679A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338443B2 (en) * 2001-04-25 2007-07-19 Proteus Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902918B1 (en) 1998-05-21 2005-06-07 California Institute Of Technology Oxygenase enzymes and screening method
US6951719B1 (en) 1999-08-11 2005-10-04 Proteus S.A. Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained
US6991922B2 (en) 1998-08-12 2006-01-31 Proteus S.A. Process for in vitro creation of recombinant polynucleotide sequences by oriented ligation
WO2001029211A2 (en) * 1999-10-19 2001-04-26 Enchira Biotechnology Corporation Method for directed evolution by random chimeragenesis on transient templates
US6534292B1 (en) 2000-05-08 2003-03-18 Genencor International, Inc. Methods for forming recombined nucleic acids
US7115403B1 (en) 2000-05-16 2006-10-03 The California Institute Of Technology Directed evolution of galactose oxidase enzymes
AU2001266978A1 (en) * 2000-06-14 2001-12-24 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US6994963B1 (en) * 2000-07-10 2006-02-07 Ambion, Inc. Methods for recombinatorial nucleic acid synthesis
WO2002006469A2 (en) * 2000-07-18 2002-01-24 Enchira Biotechnology Corporation Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
US7465567B2 (en) 2001-04-16 2008-12-16 California Institute Of Technology Peroxide-driven cytochrome P450 oxygenase variants
FR2824073B1 (en) * 2001-04-25 2003-12-19 Proteus PROCESS FOR THE IN VITRO CREATION OF RECOMBINANT POLYNUCLEOTIDE SEQUENCES BY ORIENTED LIGATION
US7226768B2 (en) 2001-07-20 2007-06-05 The California Institute Of Technology Cytochrome P450 oxygenases
EP1409666B1 (en) * 2001-07-23 2006-03-29 DSM IP Assets B.V. Process for preparing variant polynucleotides
DE10162728A1 (en) 2001-12-20 2003-07-10 Henkel Kgaa New alkaline protease from Bacillus gibsonii (DSM 14393) and washing and cleaning agents containing this new alkaline protease
DE10163884A1 (en) 2001-12-22 2003-07-10 Henkel Kgaa New alkaline protease from Bacillus sp. (DSM 14392) and detergents and cleaning agents containing this new alkaline protease
DK2390803T3 (en) 2002-03-01 2014-01-27 Codexis Mayflower Holdings Llc Methods, systems and software for identifying functional biomolecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
CN1659276A (en) 2002-04-19 2005-08-24 戴弗萨公司 Phospholipases, nucleic acids encoding them and methods for making and using them
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2275536A1 (en) 2002-08-06 2011-01-19 Verdia, Inc. AP1 amine oxidase variants
CN102618564B (en) 2003-03-06 2014-10-29 维莱尼姆公司 Amylases, nucleic acids encoding them and methods for making and using them
CA2889013C (en) 2003-03-07 2018-07-17 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
PL1613733T3 (en) 2003-04-04 2015-11-30 Basf Enzymes Llc Pectate lyases, nucleic acids encoding them and methods for making and using them
CN1863914B (en) 2003-04-29 2011-03-09 先锋高级育种国际公司 Novel glyphosate-n-acetyltransferase (GAT) genes
EP1639091B1 (en) 2003-06-17 2012-12-05 California University Of Technology Regio- and enantioselective alkane hydroxylation with modified cytochrome p450
JP2007529993A (en) 2003-07-02 2007-11-01 シンジェンタ パーティシペーションズ アーゲー Glucanases, nucleic acids encoding them and methods for making and using them
CA2891101A1 (en) 2003-08-11 2005-03-10 Basf Enzymes Llc Laccases, nucleic acids encoding them and methods for making and using them
US7435570B2 (en) 2003-08-11 2008-10-14 California Institute Of Technology Thermostable peroxide-driven cytochrome P450 oxygenase variants and methods of use
ATE482281T1 (en) 2004-06-09 2010-10-15 Pioneer Hi Bred Int PLASTID TRANSIT PEPTIDES
BRPI0510939A (en) 2004-06-16 2007-07-17 Diversa Corp compositions and methods for enzymatic chlorophyll discoloration
GB0500703D0 (en) * 2005-01-14 2005-02-23 Bioinvent Int Ab Molecular biology method
US20090038023A1 (en) 2005-03-10 2009-02-05 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them
WO2006101584A2 (en) 2005-03-15 2006-09-28 Diversa Corporation Cellulases, nucleic acids encoding them and methods for making and using them
US11214817B2 (en) 2005-03-28 2022-01-04 California Institute Of Technology Alkane oxidation by modified hydroxylases
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
US20090324574A1 (en) 2006-02-02 2009-12-31 Verenium Corporation Esterases and Related Nucleic Acids and Methods
NZ595495A (en) 2006-02-10 2013-05-31 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
WO2007095398A2 (en) 2006-02-14 2007-08-23 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
CN102690833B (en) 2006-03-07 2015-09-09 巴斯夫酶有限责任公司 Zymohexase, encode their nucleic acid and preparation and their method of use
EP2112227B1 (en) 2006-03-07 2013-05-15 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
EP1842915A1 (en) 2006-04-04 2007-10-10 Libragen Method of in vitro polynucleotide sequences shuffling by recursive circular DNA molecules fragmentation and ligation
US8252559B2 (en) 2006-08-04 2012-08-28 The California Institute Of Technology Methods and systems for selective fluorination of organic molecules
EP2444413A1 (en) 2006-08-04 2012-04-25 Verenium Corporation Methods for oil or gas well drilling, washing and/or fracturing
EP2069513A4 (en) 2006-08-04 2012-03-21 California Inst Of Techn Methods and systems for selective fluorination of organic molecules
ES2438268T3 (en) 2006-09-21 2014-01-16 Verenium Corporation Phytases, nucleic acids that encode them and methods for their production and use
ES2451266T3 (en) 2006-09-21 2014-03-26 Dsm Ip Assets B.V. Phospholipases, nucleic acids that encode them, and methods to obtain and use them
DK2479266T3 (en) 2006-12-21 2016-06-20 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids encoding them, and methods of making and using the same
NZ610301A (en) 2007-01-30 2015-03-27 Bp Corp North America Inc Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
JP5260645B2 (en) 2007-06-28 2013-08-14 フイルメニツヒ ソシエテ アノニム Modified 13-hydroperoxide lyase and uses thereof
DE102007032111B4 (en) 2007-07-09 2017-07-20 Henkel Ag & Co. Kgaa New proteases and detergents and cleaning agents containing these proteases
DE102007036756A1 (en) 2007-08-03 2009-02-05 Henkel Ag & Co. Kgaa New proteases and detergents and cleaners containing these new proteases
DE102007044415A1 (en) 2007-09-17 2009-03-19 Henkel Ag & Co. Kgaa Performance-enhanced proteases and detergents and cleaners containing these proteases
DK2205744T3 (en) 2007-10-03 2015-04-27 Bp Corp North America Inc Xylanases, nucleic acids encoding them, and methods of making and an-facing presence thereof
CA2710683A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
EP2706122A3 (en) 2008-01-03 2014-06-18 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
EP2297310A2 (en) 2008-05-23 2011-03-23 E. I. du Pont de Nemours and Company Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
CN105274125A (en) 2008-09-26 2016-01-27 托卡根公司 Gene therapy vectors and cytosine deaminases
AU2010249500B2 (en) 2009-05-21 2016-03-24 Basf Enzymes Llc Phytases, nucleic acids encoding them and methods for making and using them
UA111708C2 (en) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. METHOD OF OIL REFINING
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
BR112013003221A2 (en) 2010-08-13 2019-09-24 Pioneer Hi Bred Int chimeric polynucleotide, nucleic acid construct, cell, plant, plant explant, transgenic seed, chimeric polypeptide, method of directing a polypeptide of interest to a chloroplast, expression cassette, plant cell, isolated polypeptide
US9322007B2 (en) 2011-07-22 2016-04-26 The California Institute Of Technology Stable fungal Cel6 enzyme variants
WO2013166113A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
FR2994981B1 (en) 2012-09-05 2014-09-12 Centre Nat Rech Scient POLYPEPTIDE WITH BETA-GLUCOSIDASE ACTIVITY REINFORCED AT LOW TEMPERATURE
CN104837994A (en) 2012-12-06 2015-08-12 安捷伦科技有限公司 Molecular fabrication
US20140289906A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
US20160040149A1 (en) 2013-03-14 2016-02-11 Pioneer Hi-Bred International Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
RU2015143825A (en) 2013-03-15 2017-04-26 Пайонир Хай-Бред Интернэшнл, Инк. PHI-4 POLYPEPTIDES AND WAYS OF THEIR APPLICATION
EA030896B1 (en) 2013-08-16 2018-10-31 Пайонир Хай-Бред Интернэшнл, Инк. Insecticidal proteins and methods for their use
ES2937045T3 (en) 2013-09-13 2023-03-23 Pioneer Hi Bred Int Insecticidal proteins and methods of their use
FR3013731B1 (en) 2013-11-22 2017-09-01 Ifp Energies Now ENDOGLUCANASIC VARIANTS WITH IMPROVED ACTIVITY AND USES THEREOF
EP3102684B1 (en) 2014-02-07 2020-05-06 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
UA120608C2 (en) 2014-02-07 2020-01-10 Піонір Хай-Бред Інтернешнл, Інк. Insecticidal proteins and methods for their use
FR3022557B1 (en) * 2014-06-20 2019-01-25 Proteus EXOGLUCANASE VARIANTS WITH IMPROVED ACTIVITY AND USES THEREOF
FR3022558B1 (en) * 2014-06-20 2019-01-25 Proteus EXOGLUCANASE VARIANTS WITH IMPROVED ACTIVITY AND USES THEREOF
WO2016061206A1 (en) 2014-10-16 2016-04-21 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
US10876132B2 (en) 2015-03-11 2020-12-29 Pioneer Hi-Bred International, Inc. Insecticidal combinations of PIP-72 and methods of use
BR112017024948A2 (en) 2015-05-19 2018-07-31 Pioneer Hi Bred Int insecticide proteins and methods for their use
BR112018002535A2 (en) 2015-08-06 2018-09-25 Du Pont recombinant insecticidal polypeptide, recombinant polynucleotide, dna construct, transgenic plant or plant cell, composition, fusion protein, method for controlling a pest, method for inhibiting growth or for exterminating a pest or pest population and use of the polypeptide
CN108575091A (en) 2015-12-18 2018-09-25 先锋国际良种公司 Insecticidal protein and its application method
CN109068660B (en) 2016-05-04 2023-05-02 先锋国际良种公司 Insecticidal proteins and methods of use thereof
WO2018005411A1 (en) 2016-07-01 2018-01-04 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
CN116003539A (en) 2016-11-01 2023-04-25 先锋国际良种公司 Insecticidal proteins and methods of use thereof
BR112019012339A2 (en) 2016-12-14 2019-11-26 Pioneer Hi Bred Int recombinant insecticide polypeptide, composition, DNA construct, host cell, transgenic plant, method for inhibiting the growth or extermination of an insect pest or pest population, chimeric ipd093 polypeptide and fusion protein
CA3046226A1 (en) 2016-12-22 2018-06-28 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3052794A1 (en) 2017-02-08 2018-08-16 Pioneer Hi-Bred International, Inc. Insecticidal combinations of plant derived insecticidal proteins and methods for their use
RU2019140646A (en) 2017-05-11 2021-06-11 Пайонир Хай-Бред Интернэшнл, Инк. INSECTICIDE PROTEINS AND METHODS OF THEIR APPLICATION
CA3186978A1 (en) 2020-07-14 2022-01-20 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6110668A (en) * 1996-10-07 2000-08-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Gene synthesis method
GB9701425D0 (en) * 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
JP3018163B2 (en) * 1997-09-04 2000-03-13 工業技術院長 Thermostable Flap endonuclease from a hyperthermophilic bacterium belonging to the genus Pyrococcus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338443B2 (en) * 2001-04-25 2007-07-19 Proteus Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides

Also Published As

Publication number Publication date
FR2782323B1 (en) 2002-01-11
FR2782323A1 (en) 2000-02-18
ES2253901T3 (en) 2006-06-01
DE69928263T2 (en) 2006-08-10
AU769516C (en) 2004-11-18
DK1104457T3 (en) 2006-03-27
JP2002538763A (en) 2002-11-19
IL141373A0 (en) 2002-03-10
EP1683861A1 (en) 2006-07-26
EP1104457B1 (en) 2005-11-09
ATE309342T1 (en) 2005-11-15
DE69928263D1 (en) 2005-12-15
CA2339901C (en) 2012-02-28
NO20015787D0 (en) 2001-11-27
IL141373A (en) 2008-11-03
JP4448619B2 (en) 2010-04-14
AU769516B2 (en) 2004-01-29
WO2000009679A1 (en) 2000-02-24
CA2339901A1 (en) 2000-02-24
EP1104457A1 (en) 2001-06-06
NO20015787L (en) 2001-11-27

Similar Documents

Publication Publication Date Title
AU769516B2 (en) Method for obtaining (in vitro) recombined polynucleotide sequences, sequence banks and resulting sequences
US7718786B2 (en) Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained
US6991922B2 (en) Process for in vitro creation of recombinant polynucleotide sequences by oriented ligation
Shyamala et al. Genome walking by single-specific-primer polymerase chain reaction: SSP-PCR
Sen et al. Developments in directed evolution for improving enzyme functions
US7833759B2 (en) Method of increasing complementarity in a heteroduplex
JP6552969B2 (en) Library preparation method for directed evolution
WO2002040664A1 (en) Method of constructing nucleic acid library
US20020119535A1 (en) Method for recombining polynucleotides
AU2002338443B2 (en) Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides
US20040191772A1 (en) Method of shuffling polynucleotides using templates
US20030092023A1 (en) Method of shuffling polynucleotides using templates
AU2002338443A1 (en) Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides
US20030104417A1 (en) Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides
WO2003040376A1 (en) Method for site-directed mutagenesis of nucleic acid molecules using a single primer
CA2442096A1 (en) Methods for the preparation of polynucleotide librairies and identification of library members having desired characteristics
AU755415B2 (en) Recombination of polynucleotide sequences using random or defined primers
WO2000056876A1 (en) Mutagenesis
ZA200306203B (en) A method of increasing complementarity in a heteroduplex polynucleotide.
KR20000015984A (en) Recombination of polynucleotide sequences using random or defined primers
AU2002307170A1 (en) Methods for the preparation of polynucleotide librairies and identification of library members having desired characteristics

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20040329